Disease · MONDO_0005580
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + SOC vs Placebo + SOC: deaths from any cause | 331 of 373 | 363 of 376 | 749 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: Number of Participants With an Adverse Event (AE) | 370 of 370 | 368 of 370 | 740 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: Number of Participants Discontinuing Study Treatment Due to an AE | 90 of 370 | 74 of 370 | 740 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: serious adverse events | 207 of 370 | 204 of 370 | 740 | NCT03189719 | Trial comparisons |
| Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: deaths from any cause | 252 of 326 | 268 of 323 | 649 | NCT03783442 | Trial comparisons |
| Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: serious adverse events | 160 of 324 | 128 of 321 | 645 | NCT03783442 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE) | 301 of 314 | 288 of 296 | 610 | NCT02564263 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE) | 40 of 314 | 42 of 296 | 610 | NCT02564263 | Trial comparisons |
| Toripalimab vs Placebo: PFS Assessed Per irRECIST | 128 of 257 | 160 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: ORR Assessed Per irRECIST | 180 of 257 | 136 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: ORR(Overall Response Rate:BICR) | 178 of 257 | 134 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: DCR Assessed Per irRECIST | 232 of 257 | 218 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: DCR(Disease Control Rate:BICR ) | 229 of 257 | 211 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: deaths from any cause | 174 of 257 | 198 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: PFS | 128 of 257 | 167 of 257 | 514 | NCT03829969 | Trial comparisons |
| Toripalimab vs Placebo: serious adverse events | 93 of 257 | 74 of 257 | 514 | NCT03829969 | Trial comparisons |
| Tislelizumab vs Investigator Chosen Chemotherapy (ICC): deaths from any cause | 233 of 256 | 233 of 256 | 512 | NCT03430843 | Trial comparisons |
| Tislelizumab vs Investigator Chosen Chemotherapy (ICC): serious adverse events | 109 of 255 | 106 of 240 | 495 | NCT03430843 | Trial comparisons |
| Camrelizumab vs Investigator's Choice of Standard Therapy: deaths from any cause | 23 of 228 | 10 of 220 | 448 | NCT03099382 | Trial comparisons |
| Camrelizumab vs Investigator's Choice of Standard Therapy: serious adverse events | 71 of 228 | 52 of 220 | 448 | NCT03099382 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005580/comparisons